Ultrasmall nanomaterials have merged as promising delivery vehicles for drugs and vaccine candidates. In the context of immunity, such nanoparticles are capable of transport through lymphatics and enter lymph nodes to interact with specific immune cells. However, the interaction with antibody forming immune cells remain elusive. In my research, I studied the development and characterization of these nanomaterials followed by their evaluation using ex vivo immune technologies. Specifically, I investigated the possibility to model immune-nanomaterial interaction by engineering multiscale hydrogel-based immune organoids, using a combination of microfluidics, biomaterials, and mouse derived primary naïve immune cells.